Larimar Therapeutics Announces FDA Breakthrough Therapy Designation for Nomlabofusp in FA and Reiterates Planned BLA Submission in June 2026

Stock Information for Larimar Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Larimar Therapeutics Inc.

Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Biotech and Big Tech Drive the Morning Narrative
Larimar Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Larimar Therapeutics Reports Third Quarter 2025 Financial Results
Rosen Law Firm Encourages Larimar Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - LRMR
LRMR Investors Have Opportunity to Join Larimar Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
Rosen Law Firm Encourages Larimar Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - LRMR
Larimar Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - LRMR

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.